

APOTEX SETTLEMENT AGREEMENT
TECHNICAL CORRECTIONS MEMORANDUM

FEBRUARY 12, 2026

The Apotex Settlement Agreement, dated April 4, 2025 (the “Agreement”), as amended pursuant to the September 4, 2025 Technical Corrections Memorandum, permits the Plaintiffs’ Executive Committee, the Executive Committee of the State Attorneys General, and Apotex to meet and confer and make technical corrections to the Agreement as they agree are appropriate. See Agreement at § XIII.U. This memorandum summarizes the technical corrections issued on February 12, 2026, as well as the parties’ written agreement to revise certain deadlines.

Dates Changed by Written Agreement

On October 8, 2025, the parties agreed in writing to adjust the following deadlines. The parties further agreed to adjust the Reference Date on January 15, 2026. All agreed-upon adjustments are reflected in the below chart.

Section/Event	Original Date	Revised Date
I.FF. Initial Participation Date	October 8, 2025	November 5, 2025
I.XX. Payment Calculation Date	October 20, 2025	January 12, 2026
I.YY. Payment Date	December 19, 2025	January 29, 2026
I.EEE. Reference Date	November 7, 2025	January 23, 2026

Because the Agreement expressly permits the Parties to modify these dates by written agreement, no technical correction amendments to the Agreement are required.

The Settlement Agreement

Correction made to Section I.U to redefine the term “Effective Date,” as agreed by the parties on October 8, 2025 as part of their agreement to extend the Initial Participation Date and subsequent deadlines. Section I.U is hereby deleted and replaced by the following: “*Effective Date.*’ January 29, 2026, or such other date as mutually agreed in writing by Apotex and the Enforcement Committee.”

Corrections made to Sections V.C.4 and V.C.4.a, to account for the above-referenced extensions of the Initial Participation Date and subsequent deadlines.

Section V.C.4 is hereby deleted and replaced by the following: “No later than thirteen (13) days prior to the Payment Date, the Settlement Fund Administrator shall give notice to Apotex, the Settling States, and the Enforcement Committee of the amount of the Remediation Payment, and/or the Statewide Payment Amount for each Settling State, following the determination described in Section V.C.2 and V.C.3, and the following timeline shall apply:”

Section V.C.4.a is hereby deleted and replaced by the following: “By February 6, 2026, Apotex, any Settling State or the Enforcement Committee may dispute, in writing, the calculation of the Remediation Payment and/or the Statewide Payment Amount for a Settling State. Such disputing party must provide a written notice of dispute to the Settlement Fund Administrator, the Enforcement Committee, any affected Settling State, and Apotex identifying the nature of the dispute, the amount of money that is disputed, and the Settling State(s) affected.”

Correction made to Section IX.A as agreed by the parties on October 8, 2025 as part of their agreement to extend the Initial Participation Date and subsequent deadlines. Section IX.A is hereby deleted and replaced by the following: “*Determination to Proceed with Settlement. — Settling States.* Following the Initial Subdivision Participation Date, the Enforcement Committee shall determine whether to proceed with the Agreement on behalf of the Settling States, and the Settling States shall be bound by the determination of the Enforcement Committee. No later than December 30, 2025, the Enforcement Committee shall provide notice to Apotex of its decision. If the Enforcement Committee elects not to proceed, this Agreement will have no further effect, and all releases (including those contained in Subdivision Settlement Participation Forms and other commitments or obligations contained herein or in Subdivision Settlement Participation Forms) will be void. Within seven (7) calendar days of informing Apotex that there is sufficient participation to proceed, the Enforcement Committee will deliver all signatures and releases required by the Agreement to be provided by the Settling States to Apotex.”